Extracorporeal membrane oxygenation device is a procedure in which mechanical systems circulate blood and supply oxygen to patients with impaired cardiopulmonary function. Current venoarterial systems are associated with low patient survival rates and new treatments are needed to avoid left ventricular dilation, which is a major cause of death. In this study, a new mobile pulsatile ECMO with a pump structure that supplies pulsatile flow by using an oxygen tank as a power source is proposed. In vitro experiments conducted under mock circulation system as like patient conditions demonstrated that 2.8 L oxygen can sustain the outflow of 1 L/min of pulsatile blood flow for 53 min, while a 4.6 L tank was able to sustain the same flow for 85 min. The energy equivalent pressure evaluation index of the pulsatile blood pump shows that the mobile pulsatile ECMO could supply sufficient pulsatile blood flow compared to the existing pulsatile ECMO. Through in vitro experiments performed under mock circulation conditions, this new system was proven to supply sufficient oxygen and pulsatile blood flow using the pressure of an oxygen tank even while transporting a patient.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590354 | PMC |
http://dx.doi.org/10.1007/s13534-023-00295-7 | DOI Listing |
ASAIO J
October 2024
Division of Cardiac Surgery Department of Surgery Johns Hopkins Hospital, Baltimore, Maryland Division of Neurosciences Critical Care Department of Neurology, Neurosurgery, Anesthesiology and Critical Care Medicine Johns Hopkins Hospital, Baltimore, Maryland.
J Cardiothorac Vasc Anesth
November 2024
Department of Anesthesiology and Critical Care, University School of Medicine, Rouen University Hospital, Rouen, France; Normandie University, UNIROUEN, Rouen, France. Electronic address:
J Intensive Care
November 2024
Division of Cardiology, Department of Medicine, Faculty of Medicine, Kindai University, 377-2, Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan.
Background: The mortality rate of patients with cardiogenic shock (CS) requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) combined with Impella (ECPELLA) support remains high. Inhaled nitric oxide (iNO) improves right ventricular (RV) function, resulting in increased Impella flow, which may facilitate early withdrawal of VA-ECMO and improve survival. This study investigated the prognostic impact of iNO therapy in ECPELLA patients.
View Article and Find Full Text PDFArtif Organs
October 2024
ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland.
Eur Heart J Case Rep
October 2024
Division of Pediatric Cardiology, Department of Pediatrics and Adolescent Medicine, Pediatric Heart Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!